ESCO Q3 FY26: Sales +14%, Adjusted EPS +38% – Execution Remains Strong but Valuation Already Saturated

What happened

ESCO reported fiscal Q3 2026 sales of $339 million, up 14% year-over-year, with GAAP EPS from continuing operations rising 31% to $1.26 and adjusted EPS surging 38% to $2.20. The top-line growth likely reflects continued demand across defense, utility diagnostics, and EMC testing, consistent with the company’s compliance-critical niche positioning. While the strong adjusted EPS indicates healthy margin expansion, the release does not disclose details on acquisition integration, free cash flow, or deleveraging progress, which are key swing factors for the investment thesis. The stock’s premium valuation (TTM P/E ~38x as of the prior master report) likely persisted, meaning the beat may already be priced in. Overall, the results reinforce the company’s ability to deliver double-digit growth but leave critical questions about cash conversion and balance-sheet improvement unanswered.

Implication

The robust earnings beat suggests ESCO’s execution remains on track, with sales and adjusted EPS growth handily outpacing cost pressures, which could support the thesis if sustained. However, the lack of disclosure on FCF and deleveraging leaves the premium valuation without fresh margin-of-safety arguments. Investors should await confirmation of normalizing cash conversion and integration milestones before upgrading the stance; until then, the stock’s high multiple implies that much of the good news is already reflected.

Thesis delta

The Q3 FY2026 results show stronger-than-expected revenue and earnings growth, modestly increasing confidence in ESCO’s operational trajectory. Still, the critical watch items—acquisition integration, FCF conversion, and deleveraging—remain unaddressed, leaving the overall investment stance unchanged. A shift to BUY would require clear evidence of these factors alongside sustained organic growth, while a breakdown in margins or orders could tilt to SELL.